IO comes agonisingly close to success
Keynote-D18 might have failed on a technicality, but now cash is running out.
Allogene ditches enhanced lymphodepletion
The move comes after a death in the Alpha-3 cema-cel study.
Instilling confidence in ImmuneOnco's bispecific
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Cardiff's questionable plan yields more questions
More data from onvansertib's phase 2 study fail to convince.
